Roupret, Morgan
Brouquet, Alice
Colrat, Florian
Diez-Andreu, Pauline
Prudent, Alexis
Chartier, Mélanie
Gaudin, Anne-Françoise
Bugnard, Françoise
Chillotti, Louis
Bénard, Stève
Branchoux, Sébastien
Bellera, Carine
Negrier, Sylvie
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 7 December 2022
Accepted: 7 February 2023
First Online: 16 March 2023
Declarations
:
: MR received personal fees from Astra Zeneca, Astellas, Bristol Myers Squibb, Janssen and Roche. FC, AP, MC, AFG and SBr are employees of Bristol Myers Squibb. AB, PDI, FB and LC are employees of stève consultants, which has a research consultancy contract with Bristol Myers Squibb. SBe is the executive director of stève consultants, which has a research consultancy contract with Bristol Myers Squibb. CB received personal fees from Bristol Myers Squibb. SN received consulting fees from Bristol Myers Squibb, Ipsen, Pfizer, Merck Sharpe & Dome and Eisai.
: As part of the MR-006 submission process, this retrospective claims study using data from the French national hospitalization database (PMSI) does not require approval from an ethics committee in France.
: The source data base (PMSI) contains personal health data containing potentially identifying and sensitive patient information. In accordance with CNIL opinion n°2018-257 of 7th June 2018 on regulatory requirements and governance for processing PMSI data under MR-006 procedure, no raw data can be shared externally. The request to access PMSI data must be submitted to the Health Data Hub, the French public agency which gathers the requests, as per the MR-006 procedure. We are not permitted to publicly share these data.